IA
CNCE

IndexIQ Advisors’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

IndexIQ Advisors’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-84,631
Closed -$267K – 1565
2021
Q4 		$267K Sell
84,631
-5,469
-6% -$18.2K 0.01% 981
2021
Q3 		$295K Buy
90,100
+9,025
+11% +$31.6K 0.01% 988
2021
Q2 		$342K Sell
81,075
-1,509
-2% -$6.39K 0.01% 927
2021
Q1 		$412K Buy
+82,584
New +$667K 0.01% 503

Other funds holding CNCE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

IndexIQ Advisors's CNCE Position: Q1 2022 in Review

IndexIQ Advisors sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2022, closing a stake of 84,631 shares — an estimated $267K sold.

IndexIQ Advisors first reported a position in CNCE in Q1 2021 and held it in 4 quarters. The position peaked at $412K in Q1 2021. 53 funds tracked by Wall St. Rank hold CNCE as of Q1 2022.

  • IndexIQ Advisors reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
  • IndexIQ Advisors sold 84,631 Concert Pharmaceuticals, Inc. shares in Q1 2022, an estimated $267K.
  • IndexIQ Advisors first reported a position in Concert Pharmaceuticals, Inc. in Q1 2021 and held it in 4 quarters.
  • IndexIQ Advisors's Concert Pharmaceuticals, Inc. position peaked at $412K in Q1 2021.
  • 53 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.